VBIO

Valion Bio, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$0.51

Price (1 Year)

$52.13 $0.51

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %313.9 / %30
Non-compliant assets / Total market cap %93.2 / %30
Non-compliant revenue / Total income %100 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome.

Website

Analysis (Turkish): VBIO Hissesi Caiz mi, Helal mi? Valion Bio, Inc. Katılım Analizi